“`html
The average one-year price target for Cabaletta Bio (NasdaqGS:CABA) has been revised to $14.41 per share, representing a 15.31% increase from the prior estimate of $12.50, dated November 14, 2025. This target reflects a potential increase of 465.00% from the latest reported closing price of $2.55 per share, with a range from a low of $2.02 to a high of $31.50.
Currently, 167 funds report positions in Cabaletta Bio, a decrease of 56 (25.11%) from the last quarter. The total shares owned by institutions decreased by 6.86% to 71,651K shares, with an average portfolio weight of 0.05%, marking a 28.73% increase. The put/call ratio is at 0.02, indicating a bullish outlook.
Among significant shareholders, Bain Capital Life Sciences Investors holds 9,677K shares (10.05% ownership), while Adage Capital Partners and Jennison Associates own 8,830K (9.17%) and 8,498K (8.83%) shares, respectively. Jennison Associates increased its allocation by 113.30% since last quarter.
“`
